On May 1, 2024, Cocrystal Pharma, Inc. (COCP) announced the completion of enrollment of 78 subjects in the randomized, double blind, placebo controlled Phase 2a human challenge trial of CC-42344. Study subjects were infected with influenza A and then treated with CC-42344 or placebo. We anticipate topline results in the second half of 2024. Following FDA feedback received in the first quarter of 2024, we anticipate the company filing an IND application to conduct a late-stage trial of CC-42344 in the second half of 2024. Topline results from the single ascending dose Phase 1 trial of oral CDI-988, the company's pan coronavirus-pan norovirus oral antiviral, are expected in the second quarter of 2024. Lastly, we anticipate the initiation of a Phase 1 trial of inhaled CC-42344, a potential prophylactic and therapeutic for influenza A, in the second half of 2024.
